Nanobiotechnology and Nanomedicine Companies

Novavax is focused on creating novel, highly potent recombinant vaccines produced via cell culture. The company has developed three proprietary technology platforms: Virus-Like Particles, Novasome� paucilamellar vesicles and Micellar Nanoparticles.

Oasmia Pharmaceutical AB develops next generation cancer drugs based on nanotechnology for human and veterinary use.

Parabon NanoLabs designs and develops a new class of therapeutics and other products made possible by proprietary technology for precisely directing the self-assembly of designer macromolecules that are functionalized with molecular subcomponents (e.g., enzymes, metals or pharmaceuticals).

Particle Sciences is an integrated provider of both standard and nanotechnology approaches to drug development and delivery. The company originally pioneered use of encapsulated ingredients and nanoparticles for sunscreens and personal care. In 1999 the company licensed a portion of its nanotechnology portfolio to BASF and focused its efforts on providing services to Life Sciences companies. Now, through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution designed to minimize the time and risk between discovery and the clinic.

The company manufactures custom nanoparticle dispersions and also provides nanoparticle coating for metallic products, for instance for medical instruments.

The company developed the Artiste™ Nano Composite System for dental restoration.

The company develops, produces and markets nanotechnologies for the life sciences. They produce a variety of nano-structured surfaces for use in research and are also developing a range of products that derive from a proprietary platform technology using liquid crystals for the rapid detection of molecular interactions.

Develops, manufactures, and sells a broad range of biological based materials and services essential for the manufacture of diagnostic tests, commercial bioproduction of therapeutic drugs,including clinically annotated DNA and RNA.

The company has developed synthetic, nanostructured bone graft substitutes that will revolutionize the treatment of bone defects and fusions.

Starpharma Holdings Limited is a world leader in the development of dendrimer nanotechnology products for pharmaceutical, life-science and other applications.

Developed and manufactures a novel, biomaterial which utilizes hydrogel nanoparticles which aggregate to form a material of varying strength and elasticity which has extensive medical application including wound management and burn care, tissue regeneration and drug delivery devices.